Slide 1: Aroa Biosurgery (ARX) AGM
For personal use only Aroa Biosurgery (ARX) | AGM Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 3 August 2023 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Information in this Presentation The information in this Presentation is of a general b
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only Four product AROA ECM™ platform families for new products, line >US$3b1 TAM predominantly sold to US extensions & enables AROA’s hospitals for existing products tissue apposition platform US Direc
Slide 4: Product Portfolio
For personal use only Product Portfolio
Slide 5: AROA ECM – Structure & Biology for Regenerative Healing
|5 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 For personal use only 1. Irvine, S. M., et al. (2011). "Quantification of in vitro and in vivo angiogenes
Slide 6: AROA Product Portfolio
|6 AROA Product Portfolio Products to match wound type, stage & site of care For personal use only ACUTE: Operating Room CHRONIC: Outpatient Clinic
Slide 7: Substantial Growth Opportunities > $3B TAM
Substantial Growth Opportunities > $3B1 TAM For personal use only Complex Wounds Soft Tissue Reconstruction Total Addressable Market Total Addressable Market > $1.8B2 USD > $1.3B3 USD e.g. Diabetic Foot Ulcers, e.g. Trauma, tumour removal, e.g. Hernia repair, abdominal Venous Ulcers, Pressure Ulcers
Slide 8: Enivo – Tissue apposition platform
|8 Enivo1 – Tissue apposition platform For personal use only 12 – 24 Months Preclinical use of Enivo resulted in near complete dead space closure at the conclusion of treatment (14 days), with a median seroma area of 2% and volume of near 1.3mL, compared to an area of 98% and volume of 188.5mL for t
Slide 9: Step change in soft tissue reconstruction
|9 Step change in soft tissue reconstruction1 & For personal use only Expected to improve healing rates & quality with fewer & complications + = Soft Tissue Soft Tissue Soft Tissue Reconstruction Reconstruction Reconstruction >US$1.7B2 >US$1.0B 3 >US$2.7B4 Plastics, General, Plastics, General, Plast
Slide 10: Financial Results
| 10 For personal use only Financial Results
Slide 11: FY23 Key Financial Results
| 11 FY23 Key Financial Results For personal use only NZ$60.5m1 84%1 NZ$1.5m1 Product Revenue vs. Product Gross Margin Normalised EBITDA3 Guidance2 NZ$60-62m vs. Guidance2 84% vs. Guidance2 ~ breakeven Total revenue ~ NZ$63.4m1 84% ~NZ$45m Cash Balance 1. Presented on a reported basis. 2. Guidance w
Slide 12: Investing to transform clinical outcomes
| 12 Investing to transform clinical outcomes Impact of Enivo Investment on EBITDA For personal use only Normalised EBITDA ENIVO Normalised EBITDA (excl ENIVO) • Business highly profitable setting aside large investment 10 in Enivo (orange bars) 8 • Sacrificing short-term profitability for longer te
Slide 13: AROA Direct Sales
For personal use only AROA Direct Sales
Slide 14: Product sales
| 14 Product sales Total Product Product Sales Sales EndoformSales Endoform Sales 12% YoY growth For personal use only 13 70 12 55% YoY growth NZ$m 11 60 10 9 FY20 FY21 FY22 FY23 50 81% YoY growth MyriadSales Myriad Sales 268% YoY growth 40 15 NZ$m 10 NZ$m 30 5 0 FY20 FY21 FY22 FY23 20 TELA Bio Tela
Slide 15: TELA Bio Direct
For personal use only TELA Bio Direct
Slide 16: TELA Bio Product Sales
| 16 TELA Bio Product Sales Total Product Product Sales Sales For personal use only 80 59% YoY growth OviTex OviTexSales Sales 70 60 46% YoY growth 40 60 NZ$m 20 50% YoY growth 50 0 FY20 FY21 FY22 FY23 NZ$m 40 30 OviTex PRSSales OviTex PRS Sales 30 97% YoY growth 20 20 NZ$m 10 10 0 FY20 FY21 FY22 FY
Slide 17: Clinical Research
For personal use only Clinical Research
Slide 18: Clinical Research
| 18 Clinical Research 96 46 37 For personal use only PRESENTATIONS/ PRESENTATIONS/ PRESENTATIONS/ PURBLICATIONS PURBLICATIONS PURBLICATIONS Rapid formation of Tolerated and No negative Reduced surgical well vascularized and contaminated field inflammatory complexity4-6 functional tissue1,2 resistan
Slide 19: Clinical Research
| 19 Clinical Research Projects Initiatives FY2024 FY2025 FY2026 For personal use only • Retrospective real-world evidence (RWE) comparative Endoform™ Venous study Ulcers (RWE) • N~800+ wounds • Comparative to leading competitor device • Phase IV prospective single arm study India Study • N=100 vari
Slide 20: Manufacturing Operations
For personal use only Manufacturing Operations
Slide 21: Manufacturing and Production
| 21 Manufacturing and Production Well established commercial manufacturing facility Scalable For personal use only Unique process produces a high-quality product • Raw materials readily available in • 13 successful quality system New Zealand audits since 2014 • Modular manufacturing design • 91 sta
Slide 22: Manufacturing
| 22 Manufacturing Product Gross Gross Margin Margin Manufacturing Manufacturing Capacity Facility Capacity 85% 8% improvement 200 295% increase For personal use only 80% 150 NZ$m 75% 100 70% 50 65% 0 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Ongoing margin improvements Expanded capacity CAPEX CAPEX (
Slide 23: Outlook
For personal use only Outlook
Slide 24: FY24 Guidance
| 24 FY24 Guidance1 For personal use only NZ$72-75m 85% NZ$1-2m Product Revenue Product Gross Margin Normalised EBITDA (YoY CC growth 25 – 30%) Total revenue ~ NZ$73-76m 1. All guidance is presented on a constant currency ('CC') basis using a NZ$/US$ exchange rate of 0.65, compared to the average ex
Slide 25: Revenue growth & profitability
| 25 Revenue growth & profitability For personal use only Guidance Constant Currency @ US$0.62 @ US$0.65c • FY24 revenue growth of 25–30%, with 2022 2023 2024 2024 FY24+3 years YOY YOY NZ$m NZ$m % NZ$m % NZ$m % of revenue Myriad the key driver Product revenue 43.8 60.4 38 76 – 79 25 -30 72 – 75 25%+
Slide 26: Milestones & Catalysts
For personal use only Milestones & Catalysts
Slide 27: FY24 Catalysts
| 27 FY24 Catalysts For personal use only AROA Sales TELA AROABioSales Sales Symphony Product Momentum Momentum Momentum Launch Sales team expansion, recent Well suited to evolving Myriad is the major growth driver. Fully dedicated financing, clinical evidence, reimbursement landscape field sales te
Slide 28: Q&A
For personal use only Q&A Q&A
Slide 29: Contact Us
Contact Us Brian Ward For personal use only m +64 21 727 646 Brian.Ward@aroabio.com James Agnew m +64 21 744 915 investor@aroabio.com Visit our website www.aroa.com And find us on LinkedIn at www.linkedin.com/company/aroa-biosurgery-limited/ 64 Richard Pearse Drive, PO Box 107111, Auckland 2022, Auc